-
METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-17 Yue-fan Wang, Wen-li Zhang, Zhi-xuan Li, Yue Liu, Jian Tan, Hao-zan Yin, Zhi-chao Zhang, Xian-jie Piao, Min-hao Ruan, Zhi-hui Dai, Si-jie Wang, Chen-yang Mu, Ji-hang Yuan, Shu-han Sun, Hui Liu, Fu Yang
-
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-17 Huaqing Wang, Jifeng Feng, Yanyan Liu, Zhengzi Qian, Da Gao, Xuehong Ran, Hui Zhou, Lihong Liu, Binghua Wang, Meiyun Fang, Hebing Zhou, Zhenqian Huang, Shi Tao, Zhuowen Chen, Liping Su, Hang Su, Yu Yang, Xiaobao Xie, Huijing Wu, Ping Sun, Guoyu Hu, Aibin Liang, Zhiming Li
-
Nanomaterial‐assisted oncolytic bacteria in solid tumor diagnosis and therapeutics Bioeng. Transl. Med. (IF 7.4) Pub Date : 2024-04-17 Xiangdi Zeng, Qi Chen, Tingtao Chen
Cancer presents a formidable challenge in modern medicine due to the intratumoral heterogeneity and the dynamic microenvironmental niche. Natural or genetically engineered oncolytic bacteria have always been hailed by scientists for their intrinsic tumor‐targeting and oncolytic capacities. However, the immunogenicity and low toxicity inevitably constrain their application in clinical practice. When
-
Dissolved gases from pressure changes in the lungs elicit an immune response in human peripheral blood Bioeng. Transl. Med. (IF 7.4) Pub Date : 2024-04-17 Abigail G. Harrell, Stephen R. Thom, C. Wyatt Shields
Conventional dogma suggests that decompression sickness (DCS) is caused by nitrogen bubble nucleation in the blood vessels and/or tissues; however, the abundance of bubbles does not correlate with DCS severity. Since immune cells respond to chemical and environmental cues, we hypothesized that the elevated partial pressures of dissolved gases drive aberrant immune cell phenotypes in the alveolar vasculature
-
Pandemic punch: SARS-CoV-2 hits pancreas Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-16 Ninel Azoitei, Sandra Heller, Alexander Kleger
-
Visual interpretable MRI fine grading of meniscus injury for intelligent assisted diagnosis and treatment npj Digit. Med. (IF 15.2) Pub Date : 2024-04-15 Anlin Luo, Shuiping Gou, Nuo Tong, Bo Liu, Licheng Jiao, Hu Xu, Yingchun Wang, Tan Ding
-
Poly(A)-specific RNase (PARN) generates and regulates miR-125a-5p 3’-isoforms, displaying an altered expression in breast cancer Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-15 Luisa Tomasello, Shoshanah M. Holub, Giovanni Nigita, Rosario Distefano, Carlo M. Croce
-
Anti-lymphangiogenesis for boosting drug accumulation in tumors Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-15 Chunling Wang, Junchao Xu, Xiaoyu Cheng, Ge Sun, Fenfen Li, Guangjun Nie, Yinlong Zhang
-
Sunflower seed allergy: Identification of novel 2S‐albumins as potential marker allergens Allergy (IF 12.4) Pub Date : 2024-04-15 J. Achour, M. Reche, T. Valbuena, C. Chapuis, B. Guillon, O. Galet, K. Adel‐Patient, H. Bernard, S. Hazebrouck
-
Versatile tissue‐injectable hydrogels capable of the extended hydrolytic release of bioactive protein therapeutics Bioeng. Transl. Med. (IF 7.4) Pub Date : 2024-04-15 Eric S. Nealy, Steven J. Reed, Steven M. Adelmund, Barry A. Badeau, Jared A. Shadish, Emily J. Girard, Kenneth Brasel, Fiona J. Pakiam, Andrew J. Mhyre, Jason P. Price, Surojit Sarkar, Vandana Kalia, Cole A. DeForest, James M. Olson
Hydrogels are extensively employed in healthcare due to their adaptable structures, high water content, and biocompatibility, with FDA‐approved applications ranging from spinal cord regeneration to local therapeutic delivery. However, clinical hydrogels encounter challenges related to inconsistent therapeutic exposure, unmodifiable release windows, and difficulties in subsurface polymer insertion.
-
Deep learning evaluation of echocardiograms to identify occult atrial fibrillation npj Digit. Med. (IF 15.2) Pub Date : 2024-04-13 Neal Yuan, Nathan R. Stein, Grant Duffy, Roopinder K. Sandhu, Sumeet S. Chugh, Peng-Sheng Chen, Carine Rosenberg, Christine M. Albert, Susan Cheng, Robert J. Siegel, David Ouyang
-
Towards a common European ethical and legal framework for conducting clinical research: the GATEKEEPER experience npj Digit. Med. (IF 15.2) Pub Date : 2024-04-13 Alessia Maccaro, Vasiliki Tsiompanidou, Davide Piaggio, Alba M. Gallego Montejo, Gloria Cea Sánchez, Jordi de Batlle, Adrian Quesada Rodriguez, Giuseppe Fico, Leandro Pecchia
-
Infection with SARS-CoV-2 can cause pancreatic impairment Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-12 Wei Deng, Linlin Bao, Zhiqi Song, Ling Zhang, Pin Yu, Yanfeng Xu, Jue Wang, Wenjie Zhao, Xiuqin Zhang, Yunlin Han, Yanhong Li, Jiangning Liu, Qi Lv, Xujian Liang, Fengdi Li, Feifei Qi, Ran Deng, Siyuan Wang, Yibai Xiong, Ruiping Xiao, Hongyang Wang, Chuan Qin
-
Long‐term follow‐up of neutrophil activation after severe‐to‐critical SARS‐CoV‐2 infection: A longitudinal study Allergy (IF 12.4) Pub Date : 2024-04-13 Simon Valentin, Veronique Regnault, Jean‐Louis Gueant, Bruno Ribeiro Baptista, Thery Abel, Patrick Lacolley, Frederic Schlemmer, Ari Chaouat, François Chabot, Rosa‐Maria Gueant‐Rodriguez
-
Navigating the U.S. regulatory landscape for neurologic digital health technologies npj Digit. Med. (IF 15.2) Pub Date : 2024-04-12 Neil A. Busis, Dilshad Marolia, Robert Montgomery, Laura J. Balcer, Steven L. Galetta, Scott N. Grossman
Digital health technologies (DHTs) can transform neurological assessments, improving quality and continuity of care. In the United States, the Food & Drug Administration (FDA) oversees the safety and efficacy of these technologies, employing a detailed regulatory process that classifies devices based on risk and requires rigorous review and post-market surveillance. Following FDA approval, DHTs enter
-
Self-supervised learning for human activity recognition using 700,000 person-days of wearable data npj Digit. Med. (IF 15.2) Pub Date : 2024-04-12 Hang Yuan, Shing Chan, Andrew P. Creagh, Catherine Tong, Aidan Acquah, David A. Clifton, Aiden Doherty
-
International perspectives on measuring national digital public health system maturity through a multidisciplinary Delphi study npj Digit. Med. (IF 15.2) Pub Date : 2024-04-12 Laura Maaß, Hajo Zeeb, Heinz Rothgang
-
Whole-heart electromechanical simulations using Latent Neural Ordinary Differential Equations npj Digit. Med. (IF 15.2) Pub Date : 2024-04-11 Matteo Salvador, Marina Strocchi, Francesco Regazzoni, Christoph M. Augustin, Luca Dede’, Steven A. Niederer, Alfio Quarteroni
-
Understanding the errors made by artificial intelligence algorithms in histopathology in terms of patient impact npj Digit. Med. (IF 15.2) Pub Date : 2024-04-10 Harriet Evans, David Snead
-
Spatiotemporal evolutionary process of osteosarcoma immune microenvironment remodeling and C1QBP‐driven drug resistance deciphered through single‐cell multi‐dimensional analysis Bioeng. Transl. Med. (IF 7.4) Pub Date : 2024-04-11 Wu Xin, Ning Tang, Qiangqiang Zhao, Jianbin Xiong
The tumor immune microenvironment has manifested a crucial correlation with tumor occurrence, development, recurrence, and metastasis. To explore the mechanisms intrinsic to osteosarcoma (OS) initiation and progression, this study synthesizes multiple single‐cell RNA sequencing data sets, constructing a comprehensive landscape of the OS microenvironment. Integrating single‐cell RNA sequencing with
-
G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-10 Mingyang Zhang, Ting Chen, Xun Lu, Xiaobing Lan, Ziqiang Chen, Shaoyong Lu
-
The potential for artificial intelligence to transform healthcare: perspectives from international health leaders npj Digit. Med. (IF 15.2) Pub Date : 2024-04-09 Christina Silcox, Eyal Zimlichmann, Katie Huber, Neil Rowen, Robert Saunders, Mark McClellan, Charles N. Kahn, Claudia A. Salzberg, David W. Bates
Artificial intelligence (AI) has the potential to transform care delivery by improving health outcomes, patient safety, and the affordability and accessibility of high-quality care. AI will be critical to building an infrastructure capable of caring for an increasingly aging population, utilizing an ever-increasing knowledge of disease and options for precision treatments, and combatting workforce
-
Human-AI interaction in skin cancer diagnosis: a systematic review and meta-analysis npj Digit. Med. (IF 15.2) Pub Date : 2024-04-09 Isabelle Krakowski, Jiyeong Kim, Zhuo Ran Cai, Roxana Daneshjou, Jan Lapins, Hanna Eriksson, Anastasia Lykou, Eleni Linos
-
The algorithm journey map: a tangible approach to implementing AI solutions in healthcare npj Digit. Med. (IF 15.2) Pub Date : 2024-04-09 William Boag, Alifia Hasan, Jee Young Kim, Mike Revoir, Marshall Nichols, William Ratliff, Michael Gao, Shira Zilberstein, Zainab Samad, Zahra Hoodbhoy, Mushyada Ali, Nida Saddaf Khan, Manesh Patel, Suresh Balu, Mark Sendak
-
SM17, a new IL‐17RB‐targeting antibody, ameliorates disease progression in a mouse model of atopic dermatitis Allergy (IF 12.4) Pub Date : 2024-04-09 Lik Hang Lam, Weimin Li, Wai Chung Wu, Kai Cheung Chow, Wai Yin Dennis Au, Guolin Xu, Ge Wang, Xuchen Qian, Ka Man Ng, Shaik Abdullah Nawabjan, Muthu Iswarya Gandhi Sethuraman, Wai Yan Choi, Billy Kwok Chong Chow, Shui On Leung, Chin Wai Hui
-
Rational design of structure‐based vaccines targeting misfolded alpha‐synuclein conformers of Parkinson's disease and related disorders Bioeng. Transl. Med. (IF 7.4) Pub Date : 2024-04-09 Jose Miguel Flores‐Fernandez, Verena Pesch, Aishwarya Sriraman, Enrique Chimal‐Juarez, Sara Amidian, Xiongyao Wang, Caleb Duckering, Andrew Fang, Sara Reithofer, Liang Ma, Leonardo M. Cortez, Valerie L. Sim, Gültekin Tamgüney, Holger Wille
Synucleinopathies, including Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB), are neurodegenerative disorders caused by the accumulation of misfolded alpha‐synuclein protein. Developing effective vaccines against synucleinopathies is challenging due to the difficulty of stimulating an immune‐specific response against alpha‐synuclein without causing harmful
-
The gasdermin family: emerging therapeutic targets in diseases Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-08 Chenglong Zhu, Sheng Xu, Ruoyu Jiang, Yizhi Yu, Jinjun Bian, Zui Zou
-
Thiamine-modified metabolic reprogramming of human pluripotent stem cell-derived cardiomyocyte under space microgravity Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-08 Xinglong Han, Lina Qu, Miao Yu, Lingqun Ye, Liujia Shi, Guangfu Ye, Jingsi Yang, Yaning Wang, Hao Fan, Yong Wang, Yingjun Tan, Chunyan Wang, Qi Li, Wei Lei, Jianghai Chen, Zhaoxia Liu, Zhenya Shen, Yinghui Li, Shijun Hu
-
Histopathological biomarkers for predicting the tumour accumulation of nanomedicines Nat. Biomed. Eng. (IF 28.1) Pub Date : 2024-04-08 Jan-Niklas May, Jennifer I. Moss, Florian Mueller, Susanne K. Golombek, Ilaria Biancacci, Larissa Rizzo, Asmaa Said Elshafei, Felix Gremse, Robert Pola, Michal Pechar, Tomáš Etrych, Svea Becker, Christian Trautwein, Roman D. Bülow, Peter Boor, Ruth Knuechel, Saskia von Stillfried, Gert Storm, Sanyogitta Puri, Simon T. Barry, Volkmar Schulz, Fabian Kiessling, Marianne B. Ashford, Twan Lammers
-
Medical algorithm: Diagnosis and treatment of drug reaction with eosinophilia and systemic symptoms in adult patients Allergy (IF 12.4) Pub Date : 2024-04-08 Marie‐Charlotte Brüggen, Stephan Traidl, Yasutaka Mitamura, Sarah Walsh, Lars E. French, Nicholas Gulati, Elizabeth Phillips, Emanual Maverakis, Saskia Ingen‐Housz‐Oro
CONFLICT OF INTEREST STATEMENT The authors have no conflicts of interest to declare.
-
Preventive allergen immunotherapy with inhalant allergens in children Allergy (IF 12.4) Pub Date : 2024-04-08 Varsha Dwivedi, Sonja Kopanja, Klara Schmidthaler, Justyna Sieber, Christina Bannert, Zsolt Szépfalusi
The efficacy and safety of preventive allergen immunotherapy (pAIT) in children are currently under investigation. Here, we provide an overview of pAIT with respiratory allergens concerning the prevention of new sensitizations, allergic disease onset and progression as well as further immunomodulatory effects. Three databases were searched for clinical pAIT studies in children. Selected publications
-
Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer Mol. Ther. (IF 12.4) Pub Date : 2024-04-06 Solrun Melkorka Maggadottir, Svein Dueland, Nadia Mensali, Hanne Hamre, Per Arne Andresen, Marit Renée Myhre, Hedvig V. Juul, Iris Bigalke, Marianne Lundby, Turid Kirsti Hønnåshagen, Stein Sæbøe-Larssen, Dag Josefsen, Trond Hagtvedt, Sébastien Wälchli, Gunnar Kvalheim, Else Marit Inderberg
-
Identification of memory mechanism in tissue-resident stem cells via ANGPTL4 beyond immune cells upon viral antigen exposure Mol. Ther. (IF 12.4) Pub Date : 2024-04-06 Eun-kyung Min, Soo-Rim Kim, Choon-Mi Lee, Kun-Hee Na, Chan Hum Park, Byung-Chul Oh, YunJae Jung, In-Sun Hong
-
Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy Mol. Ther. (IF 12.4) Pub Date : 2024-04-06 Yan-Ruide Li, Yang Zhou, Jiaji Yu, Yichen Zhu, Derek Lee, Enbo Zhu, Zhe Li, Yu Jeong Kim, Kuangyi Zhou, Ying Fang, Zibai Lyu, Yuning Chen, Yanxin Tian, Jie Huang, Xinjian Cen, Tiffany Husman, Jae Min Cho, Tzung Hsiai, Jin J. Zhou, Pin Wang, Benjamin R. Puliafito, Sarah M. Larson, Lili Yang
-
Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors Mol. Ther. (IF 12.4) Pub Date : 2024-04-06 Taeyoung Ahn, Eun-Ah Bae, Hyungseok Seo
-
Fast, accurate ranking of engineered proteins by target-binding propensity using structure modeling Mol. Ther. (IF 12.4) Pub Date : 2024-04-06 Xiaozhe Ding, Xinhong Chen, Erin E. Sullivan, Timothy F. Shay, Viviana Gradinaru
-
A p21-ATD mouse model for monitoring and eliminating senescent cells and its application in liver regeneration post injury Mol. Ther. (IF 12.4) Pub Date : 2024-04-06 Miaomiao Chen, Guoxiu Wu, Yanli Lu, Shiwen Sun, Zhao Yu, Xin Pan, Wenjian Chen, Hongyu Xu, Hua Qiu, Weizhi He, Xiuhua Li, Xicheng Wang, Yi Luo, Yuan Du, Jialing Wu, Ke Wei, Wencheng Zhang, Zhongmin Liu, Zhiying He
-
TALEN-mediated intron editing of HSPCs enables transgene expression restricted to the myeloid lineage Mol. Ther. (IF 12.4) Pub Date : 2024-04-06 Eduardo Seclen, Jessica C. Jang, Aminah O. Lawal, Sylvain Pulicani, Alex Boyne, Diane Tkach, Alexandre Juillerat, Philippe Duchateau, Julien Valton
-
AM‐301, a barrier‐forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized clinical trial Allergy (IF 12.4) Pub Date : 2024-04-06 Sven Becker, Sachin Deshmukh, Ferdinandus De Looze, Veronica Francardo, Jessie Lee, Anthony McGirr, Zachary Nathan, Christopher Rook, Thomas Meyer
-
A double‐edged sword: The complex interplay between engineered nanoparticles and platelets Bioeng. Transl. Med. (IF 7.4) Pub Date : 2024-04-06 Yathreb Asaad, Danielle Nemcovsky‐Amar, Josué Sznitman, Pierre H. Mangin, Netanel Korin
Nanoparticles (NP) play a crucial role in nanomedicine, serving as carriers for localized therapeutics to allow for precise drug delivery to specific disease sites and conditions. When injected systemically, NP can directly interact with various blood cell types, most critically with circulating platelets. Hence, the potential activation/inhibition of platelets following NP exposure must be evaluated
-
Circulating tumor cells shielded with extracellular vesicle-derived CD45 evade T cell attack to enable metastasis Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-05 Chuan Yang, Xueping Wang, Kenneth K. W. To, Caimei Cui, Min Luo, Shaocong Wu, Lamei Huang, Kai Fu, Can Pan, Zeyu Liu, Teng Fan, Caibo Yang, Fang Wang, Liwu Fu
Circulating tumor cells (CTCs) are precursors of distant metastasis in a subset of cancer patients. A better understanding of CTCs heterogeneity and how these CTCs survive during hematogenous dissemination could lay the foundation for therapeutic prevention of cancer metastasis. It remains elusive how CTCs evade immune surveillance and elimination by immune cells. In this study, we unequivocally identified
-
Protein neddylation and its role in health and diseases Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-05 Shizhen Zhang, Qing Yu, Zhijian Li, Yongchao Zhao, Yi Sun
NEDD8 (Neural precursor cell expressed developmentally downregulated protein 8) is an ubiquitin-like protein that is covalently attached to a lysine residue of a protein substrate through a process known as neddylation, catalyzed by the enzyme cascade, namely NEDD8 activating enzyme (E1), NEDD8 conjugating enzyme (E2), and NEDD8 ligase (E3). The substrates of neddylation are categorized into cullins
-
Adeno-associated virus as a delivery vector for gene therapy of human diseases Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-03 Jiang-Hui Wang, Dominic J. Gessler, Wei Zhan, Thomas L. Gallagher, Guangping Gao
Adeno-associated virus (AAV) has emerged as a pivotal delivery tool in clinical gene therapy owing to its minimal pathogenicity and ability to establish long-term gene expression in different tissues. Recombinant AAV (rAAV) has been engineered for enhanced specificity and developed as a tool for treating various diseases. However, as rAAV is being more widely used as a therapy, the increased demand
-
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-03 Qiu-Zhong Pan, Jing-Jing Zhao, Liang Liu, Dong-Sheng Zhang, Li-Ping Wang, Wen-Wei Hu, De-Sheng Weng, Xiang Xu, Yi-Zhuo Li, Yan Tang, Wei-Hong Zhang, Jie-Yao Li, Xiao Zheng, Qi-Jing Wang, Yong-Qiang Li, Tong Xiang, Li Zhou, Shuang-Ning Yang, Chen Wu, Rong-Xing Huang, Jia He, Wei-Jiao Du, Lu-Jun Chen, Yue-Na Wu, Bin Xu, Qiong Shen, Yi Zhang, Jing-Ting Jiang, Xiu-Bao Ren, Jian-Chuan Xia
Fluoropyrimidine-based combination chemotherapy plus targeted therapy is the standard initial treatment for unresectable metastatic colorectal cancer (mCRC), but the prognosis remains poor. This phase 3 trial (ClinicalTrials.gov: NCT03950154) assessed the efficacy and adverse events (AEs) of the combination of PD-1 blockade-activated DC-CIK (PD1-T) cells with XELOX plus bevacizumab as a first-line
-
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-03 Jing Wang, Baizhou Li, Meng Luo, Jia Huang, Kun Zhang, Shu Zheng, Suzhan Zhang, Jiaojiao Zhou
Ductal carcinoma in situ (DCIS) represents pre-invasive breast carcinoma. In untreated cases, 25–60% DCIS progress to invasive ductal carcinoma (IDC). The challenge lies in distinguishing between non-progressive and progressive DCIS, often resulting in over- or under-treatment in many cases. With increasing screen-detected DCIS in these years, the nature of DCIS has aroused worldwide attention. A deeper
-
Challenges and opportunities of deep learning for wearable-based objective sleep assessment npj Digit. Med. (IF 15.2) Pub Date : 2024-04-04 Bing Zhai, Greg J. Elder, Alan Godfrey
In recent years the intersection of wearable technologies and machine learning (ML) based deep learning (DL) approaches have highlighted their potential in sleep research. Yet, a recent study published in NPJ Digital Medicine highlights the generalization limitations of DL models in sleep-wake classification using actigraphy data. Here, this article discusses some of the challenges and opportunities
-
Interaction of SMAC/Diablo with a survivin/BIRC5-derived peptide alters essential cancer hallmarks: Tumor growth, inflammation, and immunosuppression Mol. Ther. (IF 12.4) Pub Date : 2024-04-05 M. Santhanam, S. Kumar Pandey, A. Shteinfer-Kuzmine, A. Paul, N. Abusiam, R. Zalk, V. Shoshan-Barmatz
-
Prior respiratory syncytial viral infection contributes to severe COVID‐19 illness: A nationwide cohort study Allergy (IF 12.4) Pub Date : 2024-04-05 Hwan Jin Lee, Min Ji Kim, Jong Seung Kim, Yong Chul Lee, Jae Seok Jeong
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to be a major threat to public health around the world.1 Recently, there has been a growing recognition of the influence that prior respiratory viral infections, such as influenza, have on the outcomes of COVID-19.2 However, little is known about the long-term effects of RSV infection
-
Macrocyclic peptides: up-and-coming weapons to combat antimicrobial resistance Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-02 Wen-Jing Wang, Xiang-Min Dong, Guo-Bo Li
-
Neutrophils are shaped by the tumor microenvironment: novel possibilities for targeting neutrophils in cancer Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-02 Carlos Silvestre-Roig, Lydia Kalafati, Triantafyllos Chavakis
-
Optimizing oncolytic virus design: a “Swiss army knife” approach to create a systemically delivered therapeutic Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-02 Carolina S. Ilkow, John Cameron Bell
-
Mex-3 RNA binding family member A (MEX3A)/circMPP6 complex promotes colorectal cancer progression by inhibiting autophagy Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-02 Ri-Xin Chen, Shui-Dan Xu, Min-Hua Deng, Shi-Hui Hao, Jie-Wei Chen, Xiao-Dan Ma, Wei-Tao Zhuang, Jing-Hua Cao, Yong-Rui Lv, Jin-Long Lin, Si-Yu Li, Gui-Bin Qiao, Dan Xie, Feng-Wei Wang
RNA-binding proteins (RBPs)-RNA networks have contributed to cancer development. Circular RNAs (circRNAs) are considered as protein recruiters; nevertheless, the patterns of circRNA-protein interactions in colorectal cancer (CRC) are still lacking. Processing bodies (PBs) formed through liquid-liquid phase separation (LLPS) are membrane-less organelles (MLOs) consisting of RBPs and RNA. Previous evidence
-
Messing with cancer therapy: how the melanoma phenotype predicts checkpoint inhibitor response Signal Transduct. Target Ther. (IF 39.3) Pub Date : 2024-04-01 Svenja Meierjohann, Corine Bertolotto
-
Extracellular vesicle miRNAs drive aberrant macrophage responses in NSAID‐exacerbated respiratory disease Allergy (IF 12.4) Pub Date : 2024-04-04 Franziska Hartung, Pascal Haimerl, Sonja Schindela, Veronika Mussack, Benedikt Kirchner, Fiona D. R. Henkel, Ulrike Bernhardt, Ulrich M. Zissler, Rachel Santarella‐Mellwig, Michael Pfaffl, Carsten B. Schmidt‐Weber, Adam M. Chaker, Julia Esser‐von Bieren
-
Patterns of allergen recognition in Ligustrum polysensitized patients: An immunoproteomics approach Allergy (IF 12.4) Pub Date : 2024-04-04 Raúl Porras‐Gutiérrez‐de‐Velasco, Blessy Maruthukunnel‐Mani, Juan Carlos Vizuet‐de‐Rueda, Josaphat Miguel Montero‐Vargas, Luis M. Teran
Members of the Oleaceae family, including Ligustrum (privet), Olea (olive), and Fraxinus (ash), are recognized as important causes of allergenic respiratory diseases worldwide. In Mexico City, nearly 37% of allergic patients have been reported to show sensitization to Ligustrum lucidum pollen, correlating with sensitization to Fraxinus, a very abundant tree in the city.1 Lig v 1, a homolog of Ole e
-
Evaluating large language models as agents in the clinic npj Digit. Med. (IF 15.2) Pub Date : 2024-04-03 Nikita Mehandru, Brenda Y. Miao, Eduardo Rodriguez Almaraz, Madhumita Sushil, Atul J. Butte, Ahmed Alaa
Recent developments in large language models (LLMs) have unlocked opportunities for healthcare, from information synthesis to clinical decision support. These LLMs are not just capable of modeling language, but can also act as intelligent “agents” that interact with stakeholders in open-ended conversations and even influence clinical decision-making. Rather than relying on benchmarks that measure a
-
This Month in JAAD Case Reports: June 2024 Pauci-nail lichen planus J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-03 Brett Sloan MD
-
A serine-conjugated butyrate prodrug with high oral bioavailability suppresses autoimmune arthritis and neuroinflammation in mice Nat. Biomed. Eng. (IF 28.1) Pub Date : 2024-04-01 Shijie Cao, Erica Budina, Michal M. Raczy, Ani Solanki, Mindy Nguyen, Taryn N. Beckman, Joseph W. Reda, Kevin Hultgren, Phillip S. Ang, Anna J. Slezak, Lauren A. Hesser, Aaron T. Alpar, Kirsten C. Refvik, Lucas S. Shores, Ishita Pillai, Rachel P. Wallace, Arjun Dhar, Elyse A. Watkins, Jeffrey A. Hubbell
Butyrate—a metabolite produced by commensal bacteria—has been extensively studied for its immunomodulatory effects on immune cells, including regulatory T cells, macrophages and dendritic cells. However, the development of butyrate as a drug has been hindered by butyrate’s poor oral bioavailability, owing to its rapid metabolism in the gut, its low potency (hence, necessitating high dosing), and its
-
Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression Nat. Biomed. Eng. (IF 28.1) Pub Date : 2024-04-01 Olivia Sirpilla, R. Leo Sakemura, Mehrdad Hefazi, Truc N. Huynh, Ismail Can, James H. Girsch, Erin E. Tapper, Michelle J. Cox, Kendall J. Schick, Claudia Manriquez-Roman, Kun Yun, Carli M. Stewart, Ekene J. Ogbodo, Brooke L. Kimball, Long K. Mai, Omar L. Gutierrez-Ruiz, Makena L. Rodriguez, Martina Gluscevic, Daniel P. Larson, Alex M. Abel, Wesley A. Wierson, Gloria Olivier, Elizabeth L. Siegler, Saad
Allogeneic mesenchymal stromal cells (MSCs) are a safe treatment option for many disorders of the immune system. However, clinical trials using MSCs have shown inconsistent therapeutic efficacy, mostly owing to MSCs providing insufficient immunosuppression in target tissues. Here we show that antigen-specific immunosuppression can be enhanced by genetically modifying MSCs with chimaeric antigen receptors
-
Syphilis: Fearful when not feared J. Am. Acad. Dermatol. (IF 13.8) Pub Date : 2024-04-02 Kathyana P. Santiago Mangual BA, Arianne Shadi Kourosh MD MPH